Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Haemonetics Corporation's second-quarter fiscal 2026 earnings call highlighted both promising advancements and areas requiring attention.</li><li>Overall reported revenues declined by 5% to $327 million, primarily due to portfolio transitions like the divestiture of the whole blood product line, which impacted performance negatively by $48 million in the quarter.</li><li>However, excluding these factors, organic revenue growth was 9% for the quarter, reflecting strong underlying performance.</li></ul>

Haemonetics Corporation's second-quarter fiscal 2026 earnings call highlighted both promising advancements and areas requiring attention.Overall reported revenues declined by 5% to $327 million, primarily due to portfolio transitions like the divestiture of the whole blood product line, which impacted performance negatively by $48 million in the quarter.However, excluding these factors, organic revenue growth was 9% for the quarter, reflecting strong underlying performance.

Haemonetics Corporation: The Vascular Closure Comeback Plan—Can VASCADE Reaccelerate Growth?

<ul><li>Haemonetics Corporation reported its third-quarter fiscal 2025 financial results, indicating both strengths and challenges within its various business segments.</li><li>The company achieved a revenue of $349 million, reflecting a 4% increase on a reported basis but remaining flat organically.</li><li>Adjusted earnings per share improved by 14% to $1.19.</li></ul>

Haemonetics Corporation reported its third-quarter fiscal 2025 financial results, indicating both strengths and challenges within its various business segments.The company achieved a revenue of $349 million, reflecting a 4% increase on a reported basis but remaining flat organically.Adjusted earnings per share improved by 14% to $1.19.

Haemonetics Corporation: Diversification Into High-Margin Med-Surg Offerings As A Critical Growth Lever!

<ul><li>Haemonetics Corporation reported solid financial results for the second quarter of fiscal year 2025, reflecting both positive growth trajectories and some ongoing challenges.</li><li>The company achieved a total revenue of $346 million, marking a 9% increase on a reported basis and 4% growth organically, primarily driven by its Hospital business.</li><li>The adjusted earnings per share for the quarter were $1.12, a 13% increase compared to the previous year, underlining improved financial performance.</li></ul>

Haemonetics Corporation reported solid financial results for the second quarter of fiscal year 2025, reflecting both positive growth trajectories and some ongoing challenges.The company achieved a total revenue of $346 million, marking a 9% increase on a reported basis and 4% growth organically, primarily driven by its Hospital business.The adjusted earnings per share for the quarter were $1.12, a 13% increase compared to the previous year, underlining improved financial performance.

Haemonetics Corporation: Accelerating International Expansion Strategy To Change The Game! - Major Drivers

<ul><li>Haemonetics Corporation's first quarter fiscal year 2025 results reveal mixed outcomes in a challenging market scenario.</li><li>The company reported a revenue of $336 million, which represents an 8% increase on a reported basis and a 3% organic growth.</li><li>Despite the revenue growth, the adjusted earnings per diluted share decreased by 3% to $1.02, reflecting some strain from operational challenges and the dynamic market conditions.</li></ul>

Haemonetics Corporation's first quarter fiscal year 2025 results reveal mixed outcomes in a challenging market scenario.The company reported a revenue of $336 million, which represents an 8% increase on a reported basis and a 3% organic growth.Despite the revenue growth, the adjusted earnings per diluted share decreased by 3% to $1.02, reflecting some strain from operational challenges and the dynamic market conditions.

Haemonetics Corporation: Expansion of the Vascular Closure Market & Other Major Drivers

<ul><li>Haemonetics Corporation has demonstrated significant progress in its business strategies, leading to notable growth in its latest fiscal results, despite facing challenges and changes.</li><li>Noteworthy is the company’s bold shift in integrating service revenue within its commercial units and adjusting its reporting formats.</li><li>These efforts aim to streamline internal synergies and enhance accountability, potentially offering improved customer service and driving robust growth in the new work structure.</li></ul>

Haemonetics Corporation has demonstrated significant progress in its business strategies, leading to notable growth in its latest fiscal results, despite facing challenges and changes.Noteworthy is the company’s bold shift in integrating service revenue within its commercial units and adjusting its reporting formats.These efforts aim to streamline internal synergies and enhance accountability, potentially offering improved customer service and driving robust growth in the new work structure.

Haemonetics Corporation: A Tale Of Hospital Business Growth and Portfolio Expansion! - Major Drivers

United States

Haemonetics Corporation designs, manufactures, and markets automated blood processing systems.  The Company's products are for use in surgical blood salvage, blood component collections, and plasma collections.  Haemonetics markets its products worldwide, primarily outside the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Haemonetics Corp (HAE US)

Haemonetics Corporation: The Vascular Closure Comeback Plan—Can VASCADE Reaccelerate Growth?

Haemonetics Corporation's second-quarter fiscal 2026 earnings call highlighted both promising advancements and areas requiring attention. Overall...

Baptista Research

Haemonetics Corporation: Diversification Into High-Margin Med-Surg Offerings As A Critical Growth Lever!

Haemonetics Corporation reported its third-quarter fiscal 2025 financial results, indicating both strengths and challenges within its various...

Baptista Research

Haemonetics Corporation: Accelerating International Expansion Strategy To Change The Game! - Major Drivers

Haemonetics Corporation reported solid financial results for the second quarter of fiscal year 2025, reflecting both positive growth trajectories...

Baptista Research

Haemonetics Corporation: Expansion of the Vascular Closure Market & Other Major Drivers

Haemonetics Corporation's first quarter fiscal year 2025 results reveal mixed outcomes in a challenging market scenario. The company reported a...

Baptista Research

Haemonetics Corporation: A Tale Of Hospital Business Growth and Portfolio Expansion! - Major Drivers

Haemonetics Corporation has demonstrated significant progress in its business strategies, leading to notable growth in its latest fiscal results,...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)